Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pacific Hospital Supply Co., Ltd (4126.TWO)
Taipei, HSQ, TW
Pacific Hospital Supply Co., Ltd., together with its subsidiaries, manufactures, processes, and sells medical disposable products and equipment in Taiwan. The company’s disposable medical devices include tubings, bags, bottles, closed wound drainage systems, surgical suction instruments, respiratory therapy products, and other products. It also provides medical gas systems, such as medical gas outlets, secondary equipment, accessories, and pipeline equipment, as well as pipeline system design and maintenance services. Pacific Hospital Supply Co., Ltd. offers its products for health care industry clients. The company also exports its products to approximately 80 countries and regions. Pacific Hospital Supply Co., Ltd. was founded in 1977 and is headquartered in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.25% | -0.13% | -1.48% | -2.33% | -9.83% | -6.34% | -14.01% | -6.78% | +14.16% | -19.48% | +565.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+2.6% Q1'26: -3.8% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-14.5% Q1'26: -21.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+18.7% Q1'26: +11.2% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+19.7% ★ Q1'26: +20.0% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+17.0% ★ Q1'26: +16.4% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.71× ★ Q1'26: 0.71× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.62B
est: 1.62B (+0.0%)
|
1.69B
est: 1.69B (0.0%)
|
1.73B
est: 1.77B (-2.2%)
|
1.82B
est: 1.82B (+0.0%)
|
2.04B
est: 2.04B (0.0%)
|
2.17B
est: 2.17B (+0.2%)
|
2.02B
est: 2.05B (-1.3%)
|
2.18B
est: 2.17B (+0.6%)
|
2.32B
est: 2.23B (+4.2%)
|
2.35B
est: 2.35B (-0.1%)
|
2.41B
est: 2.44B (-1.4%)
|
2.45B
2.45B – 2.45B
+0.4% YoY
|
| EBITDA |
489.81M
est: 462.98M (+5.8%)
|
489.85M
est: 482.60M (+1.5%)
|
429.87M
est: 506.78M (-15.2%)
|
433.66M
est: 520.30M (-16.7%)
|
714.20M
est: 582.83M (+22.5%)
|
603.59M
est: 619.15M (-2.5%)
|
602.81M
est: 584.05M (+3.2%)
|
568.57M
est: 620.36M (-8.3%)
|
673.80M
est: 625.55M (+7.7%)
|
705.13M
est: 659.04M (+7.0%)
|
612.06M
est: 685.30M (-10.7%)
|
688.10M
688.10M – 688.10M
+0.4% YoY
|
| EBIT |
422.91M
est: 350.29M (+20.7%)
|
416.03M
est: 365.13M (+13.9%)
|
313.30M
est: 383.43M (-18.3%)
|
283.17M
est: 393.65M (-28.1%)
|
544.60M
est: 440.97M (+23.5%)
|
433.96M
est: 468.44M (-7.4%)
|
442.64M
est: 441.89M (+0.2%)
|
420.51M
est: 469.36M (-10.4%)
|
531.22M
est: 442.69M (+20.0%)
|
563.36M
est: 466.39M (+20.8%)
|
473.53M
est: 484.97M (-2.4%)
|
486.96M
486.96M – 486.96M
+0.4% YoY
|
| Net Income |
351.31M
est: 351.76M (-0.1%)
|
332.67M
est: 332.82M (0.0%)
|
237.09M
est: 257.59M (-8.0%)
|
216.35M
est: 209.48M (+3.3%)
|
459.12M
est: 479.86M (-4.3%)
|
328.72M
est: 335.58M (-2.0%)
|
386.42M
est: 364.92M (+5.9%)
|
331.40M
est: 324.97M (+2.0%)
|
420.79M
est: 406.88M (+3.4%)
|
447.85M
est: 455.29M (-1.6%)
|
382.87M
est: 445.79M (-14.1%)
|
389.52M
389.52M – 389.52M
-12.6% YoY
|
| SGA |
166.17M
est: 133.83M (+24.2%)
|
170.97M
est: 139.50M (+22.6%)
|
166.63M
est: 146.49M (+13.7%)
|
173.77M
est: 150.40M (+15.5%)
|
188.92M
est: 168.48M (+12.1%)
|
192.12M
est: 178.97M (+7.3%)
|
162.72M
est: 168.83M (-3.6%)
|
187.36M
est: 179.32M (+4.5%)
|
184.31M
est: 175.75M (+4.9%)
|
184.05M
est: 185.16M (-0.6%)
|
169.09M
est: 192.54M (-12.2%)
|
193.33M
193.33M – 193.33M
+0.4% YoY
|
| EPS |
4.84
est: 4.81 (+0.5%)
|
4.58
est: 4.56 (+0.5%)
|
3.26
est: 3.53 (-7.5%)
|
2.98
est: 2.87 (+3.9%)
|
6.32
est: 6.57 (-3.8%)
|
4.53
est: 4.59 (-1.4%)
|
5.32
est: 4.99 (+6.5%)
|
4.56
est: 4.45 (+2.5%)
|
5.80
est: 5.57 (+4.2%)
|
6.17
est: 6.23 (-1.0%)
|
5.27
est: 6.10 (-13.6%)
|
5.33
5.33 – 5.33
-12.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 168.7K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 74.8K | 0.28% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 58.7K | 0.29% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 10.2K | 0.46% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 2.6K | 0.44% |
| 6 | Avantis Emerging Markets Value ETF AVES | 0.00% | 2.5K | 0.36% |
| 7 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 28.0K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| An-Ting Chung | Chairperson | 17M | female |
| Tim Chiang | GM & Corporate Governance Officer | 9M | male |
| Yu-Shiu Huang | Head of Accounting & Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4126.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
